What Has Been the Progress and Growth of the Adult Malignant Glioma Therapeutics Market in Recent Years?
The adult malignant glioma therapeutics market has seen considerable growth due to a variety of factors.
• There has been a significant expansion in the adult malignant glioma therapeutics market size in the last few years. It is predicted to rise from $2.25 billion in 2024 to $2.48 billion in 2025, with a compound annual growth rate (CAGR) of 10.4%.
The surge during the historical period can be linked to higher incidence rates, patient advocacy initiatives, and the adoption of personalized medicine strategies.
What Is The Expected Growth In The Adult Malignant Glioma Therapeutics Market?
The adult malignant glioma therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for therapeutics for adult malignant glioma is anticipated to experience robust growth in the coming years. It is predicted to reach $3.55 billion by 2029, with a compound annual growth rate (CAGR) of 9.4%.
The predicted growth during the forecast period is due to advancements in immunotherapy, targeted therapies, the discovery of biomarkers, application of liquid biopsy, and broadened access programs. Significant trends during this period include development of drugs centered on the patient, expedited and breakthrough designations, enhancement in drug delivery systems, cooperative research initiatives, and incorporation of artificial intelligence.
Which Drivers Are Accelerating Growth In The Adult Malignant Glioma Therapeutics Market?
The rise in brain tumor cases is projected to spearhead the growth of the adult malignant glioma therapeutics market. Brain tumors are irregular tissue masses wherein normal cellular regulatory mechanisms are ineffective, leading to cell proliferation without any control. Adult malignant glioma is a brain tumor variant distinguished by an abnormal and unchecked cell growth. The treatment for adult malignant glioma incorporates an amalgamation of surgery, radiation therapy, and chemotherapy. For example, the American Cancer Society, a nonprofit cancer advocacy organization in the US, reported in January 2023 that the cases of brain and nervous system cancer surged to 24,810 in that year, an increase of 3.85% from 23,890 in 2020. Thus, the rising incidence of brain tumors is boosting the adult malignant glioma therapeutics market. Financial assistance from the government to stimulate brain cancer research is predicted to fuel the growth of the adult malignant glioma therapeutics market in the future. Government funding encompasses pecuniary aid offered by governmental bodies, whether federal, state, or local, to various organizations, projects, initiatives, programs, or individuals. Such funding backing brain cancer research proves advantageous for adult malignant glioma therapeutics by supporting the evolution of new treatments, specialized drug development, targeting pyrimidine synthesis, and the approval of orphan drugs. For example, in June 2023, the Department of Health and Aged Care in Australia initiated the Australian Brain Cancer Mission with a funding of $136.66 million to back brain cancer research. The initiative aims to double survival rates and thereby enhance the quality of life for brain cancer patients, including those with anaplastic astrocytoma. Thus, government funding supporting brain cancer research bolsters the adult malignant glioma therapeutics market.
What Are The Primary Segments In The Global Adult Malignant Glioma Therapeutics Market?
The adult malignant glioma therapeutics market covered in this report is segmented –
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users
Subsegments:
1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies
2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies
3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies
4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies
5) By Other Types: Rare Gliomas, Emerging Therapies
Pre-Book The Adult Malignant Glioma Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Adult Malignant Glioma Therapeutics Market?
Large corporations involved in the adult malignant glioma therapeutics field are creating cutting-edge products like small molecule targeted degraders to enhance customer treatment experience. These are drugs utilizing small molecules to trigger the breakdown of certain proteins by targeting a particular protein of interest (POI) and an E3 ubiquitin ligase. To illustrate, in February 2023, Beactica Therapeutics AB, a precision oncology company hailing from Sweden, was granted approval for orphan drug designation by the U.S. Food and Drug Administration (FDA) for their product, BEA-17, designed to treat glioblastoma (GBM). BEA-17, a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, both implicated in the development of a range of cancers, functions by breaking down LSD1 and CoREST. This process results in the reactivation of tumor suppressor genes and effectively halts cancer cell growth.
Who Are the Key Players In The Adult Malignant Glioma Therapeutics Market?
Major companies operating in the adult malignant glioma therapeutics market report are:
• Johnson & Johnson Private Limited
• Pfizer Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Allergan PLC
• AbbVie Inc.
• Novartis AG
• Bayer AG
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Bristol-Myers Squibb Company
• Abbott Laboratories
• AstraZeneca PLC
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• GT Medical Technologies Inc.
• Lupin Limited
• Mylan NV
• Sanofi SA
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Genetech Inc.
• Amneal Pharmaceuticals LLC
• Emcure Pharmaceuticals Limited
• Novocure Ltd.
• Arbour Pharmaceuticals LLC
• Basilea Pharmaceuticals Ltd.
What Is The Most Dominant Region In The Adult Malignant Glioma Therapeutics Market?
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
